Adverse Drug Reaction
Drugs raise mitochondrial toxicity risk in HIV/hepatitis C-coinfected patients
Published in Hepatitis Weekly, October 24th, 2005
Researchers in France conducted a study "to evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/(HCV)-coinfected patients receiving anti-HCV therapy. All cases of symptomatic mitochondrial toxicity reported in 416 patients participating in an open, randomized trial of peg-interferon alpha-2b plus ribavirin vs. interferon alpha-2b plus ribavirin for 48 weeks were reviewed."
"Associations with antiretroviral treatments and with clinical and laboratory findings were sought by univariate and multivariate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-10-24)
More Articles from Hepatitis Weekly
- Diagnostics
Phased screening uncovers the antiviral activity of hepatitis C virus therapy - Hepatitis B Therapy
C-13-caffeine breath test detects chronic hepatitis B response to lamivudine - Hepatitis B Therapy
RNA interference fights hepatitis B virus replication in murine models - Hepatitis C Therapy
Serum alpha-fetoprotein levels decline in patients who receive hepatitis C virus therapy - Alcohol Use
S-adenosylmethionine averts liver cancer growth in alcohol hepatitis models - Cancer Risk Factors
Hepatitis C virus may account for some cases of splenic large B-cell lymphoma - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
